RSV Vaccine Demonstrates 43.3% Effectiveness Three Years Post-Administration

Tuesday, 8 October 2024, 17:48

RSV vaccine effectiveness is highlighted with the latest findings showing a notable 43.3% efficacy rate three years after administration. GSK's Arexvy vaccine presents crucial data for those aged 60 and older. Understanding the long-term impact of this vaccine is vital for public health strategies.

Mcknights — RSV Vaccine Demonstrates 43.3% Effectiveness Three Years Post-Administration

The recent *GSK* announcement confirms that its Arexvy vaccine against respiratory syncytial virus (RSV) shows a remarkable 43.3% effectiveness in preventing severe illness even three years after administration. Data highlights the importance of vaccination for those aged 60 and older, emphasizing the need for ongoing public health discussions regarding RSV prevention.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts